Elan moves to raise share of RP market

International pharmaceutical and research company Elan Corp. plans to increase its share of the multi-billion specialty drug and healthcare market in the country this year.

This was announced by Daniel Reyes, country manager of Elan Pharmaceutical Corp., and the company's base for its Philippine operations.

Elan Pharmaceutical's international headquarters is in Dublin, Ireland and established its operations in the Philippines some 14 years ago.

Reyes said Elan is Ireland's largest publicly quoted company on the Dublin stock exchange with sales of over $1 billion and almost $10-billion market capitalization.

The global company is a leading worldwide specialty pharmaceutical company focused on the discovery, development and marketing of therapeutic products and services in neurology and pain management and on the development and commercialization of products using its extensive range of proprietary drug delivery technologies.

Our major customers worldwide are patients with Parkinson's disease, movement disorder and epilepsy among others, Reyes said.

On the drug delivery side, our customers are international pharmaceutical companies and others who wish to license our technology, he added.

Reyes said Elan Pharmaceutical's strategy to further increase its local market share is anchored on the strength of its products and technologies, and on its research capabilities.

Our forward push in the local market is backed by our integrated discovery, development and marketing capabilities, Reyes said.

He said these capabilities respond to the growing local and worldwide demand for specialty drugs, especially among patients afflicted by chronic pain and ailments of the nervous system.